Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aimed to determine whether registrar involvement in minimally invasive distal pancreatectomy (MIDP) was associated with adverse outcomes.
From January 2009 to March 2020, data of all consecutive patients requiring distal pancreatectomy in our public tertiary hospital were prospectively collected and retrospectively analyzed.
Registrars were progressively involved for MIDP since 2009 and their experience was: < 5 open pancreatic resections, < 5 MIDP and at least 30 advanced minimally invasive gastrointestinal resections.
Outcome of patients who underwent either distal pancreatectomy by the consultant or registrars were compared.
Our primary outcome was the conversion rate. The secondary outcomes were 90-days postoperative outcomes including CR-POPF defined and classified according to the 2016 ISGPF definition.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 (Registrar) | Group 1 (Registrar): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a registrar (young specialist surgeon) |
| |
| Group 2 (Consultant) | Group 2 (Consultant): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a consultant (expert) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Minimally invasive distal pancreatectomy | Procedure | Minimally invasive distal pancreatectomy |
|
| Measure | Description | Time Frame |
|---|---|---|
| open conversion rate | Necessity to swith from minimally invasive approach to open approach during laparoscopy | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of surgery | Duration of surgery | 1 day |
| Intraoperative bloodloss | Intraoperative bloodloss | 1 day |
Not provided
Inclusion criteria:
- Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology between 2009-2020
Exclusion criteria:
Not provided
Not provided
Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology
Not provided
| Name | Affiliation | Role |
|---|---|---|
| REGIS SOUCHE | University Hospital, Montpellier | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Uhmontpellier | Montpellier | 34295 | France |
NC
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Intraoperative transfusion | Intraoperative transfusion | 1 day |
| severe complications Clavien Dindo>3 | severe complications Clavien Dindo>3 | 90 days postoperative |
| postoperative complications | postoperative complications | 90 days postoperative |
| clinically relevant postoperative fistula | clinically relevant postoperative fistula (2016 ISGPF definition) | 90 days postoperative |
| lenght of hospital stay | lenght of hospital stay | 90 days postoperative |
| readmission rate | readmission rate | 90 days postoperative |
| reoperation rate | reoperation rate | 90 days postoperative |